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Background: Chronic lung infection with Pseudomonas aeruginosa is the main cause
of mortality in patients with cystic fibrosis (CF). Sinus colonization with P. aeruginosa
often precedes intermittent lung colonization, and intermittent colonization precedes
chronic infection.When P. aeruginosa colonizes the sinuses, elevated immunoglobulin
A (IgA) levels specific against P. aeruginosa can be detected in saliva. Therefore, we
hypothesized that increasing levels of IgA in saliva can be detected before P.
aeruginosa lung colonization.
Methods: Forty‐nine CF patients free from lung colonization with P. aeruginosa or
other Gram‐negative bacteria (GNB) were included in this prospective study. Saliva
and serum samples were collected and examined for IgA antibodies against P.
aeruginosa with at least 6‐month intervals between sequential samples.
Results: A total of 110 measurements of IgA in saliva were included. During a
median of 8.5‐month follow‐up, 25 patients changed their lung infection status. We
were able to construct a statistical model that for a given value of IgA in saliva, could
predict the probability of a change in lung infection status within the next 8.5 months
(median): p = 1 / (1 + exp(−(−0.9582 + 1.6518*IgA)). The model includes a prediction
band where 95% of new measurements are predicted to fall within. The model, how-
ever, failed to reach statistical significance (P = 0.056 1‐tailed), probably because of
lack of power.
Conclusion: The saliva IgA model may predict a worsening in lung infection status
presumably acting as a surrogate marker of P. aeruginosa bacterial sinusitis. The model
may identify patients at risk of subsequent lung colonization and, thus, be a helpful
clinical tool, but it should be tested in studies with larger sample sizes to evaluate
its utility.
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Chronic lung infection with Pseudomonas aeruginosa is associated with
bronchopulmonary inflammation, tissue damage, bronchiectasis, and
progressive declining lung function, and is the main cause of prema-
ture death or lung transplantation in patients with cystic fibrosis
(CF).1 Intermittent lung colonization precedes chronic infection,2 and
preventing or postponing chronicity is of paramount importance in
CF treatment.3 Important indicators for chronic lung infection include
increasing levels of Immunoglobulin G (IgG) antibodies against P.
aeruginosa in serum 2 to 3 years before the lung infections becomes
chronic and growth of mucoid P. aeruginosa strains in sputum.4 Respi-
ratory infection with P. aeruginosa causes increases of antibodies
against P. aeruginosa both systemically5 and locally in saliva, tears,
and nasal secretions.6 Secretory immunoglobulin A (s‐IgA) is the
predominating antibody on mucosal surfaces.6,7
In the initial stages of lung colonization, P. aeruginosa can usually
be eradicated. However, patients are usually re‐colonized with the
same clone from the patients' own sinuses; thus, the sinuses can func-
tion as a sustainable bacterial reservoir.8-10 In many cases, colonization
of paranasal sinuses may precede intermittent lung colonization.11
This encourages efficient treatments of sinuses that may subsequently
spare colonization of the lower airways. Unfortunately, no non‐inva-
sive method can currently detect P. aeruginosa sinusitis with a high
specificity or sensitivity. Possible methods include nasal lavage9 or
swabs from the middle meatus; however, in our experience (unpub-
lished), there is a risk of false negative results, because the pathogenic
bacteria can be present in, for example, the frontal or sphenoid
sinuses. In a diseased sinus with mucosal oedema, nasal lavage may
not enter these cavities, encouraging research in other modalities.
However, the way of drainage from any paranasal sinus is through
its ostium. Therefore, secretions may not be ultimately hidden from
sampling, but they will appear in descending airways at some time.
Our research group has shown that when P. aeruginosa colonizes
the sinuses, elevated secretory (s) ‐IgA levels can be detected in nasal
mucosa and saliva. Further, values are significantly higher in patients'
lung colonized with P. aeruginosa or other GNB.6
Therefore, we hypothesized that increasing levels of s‐IgA in
saliva against P. aeruginosa standard antigen (St‐Ag) precede intermit-
tent P. aeruginosa lung colonization.
In this prospective study, saliva samples were collected and ana-
lyzed in order to test if P. aeruginosa or GNB lung colonization could
be predicted. If so, we provide a diagnostic antibody assay for early
detection of P. aeruginosa sinus colonization, and an eradication
attempt could be initiated. In this way, the lungs may be spared from
colonization, inflammation, and irreversible lung damage. Eradication
regimens include endoscopic sinus surgery (ESS) with adjuvant ther-
apy including systemic antibiotics, nasal irrigation with saline and anti-
biotics,12,13 or nasal inhalation of antibiotics.14
2 | MATERIAL AND METHODS
2.1 | Patients
The CF diagnosis was based on characteristic clinical features, abnor-
mal sweat electrolytes, and genotypes. All CF patients from theCopenhagen CF Centre are followed in the out‐patient clinic every
month. A clinical exam is followed by routine microbiological surveil-
lance of sputum samples or samples obtained by endolaryngeal suc-
tion. Lower airway origin of the samples is verified by microscopy.
Further, regularly blood samples are taken and analyzed for anti‐bac-
terial antibodies, as described previously.6,15 All patients diagnosed
with CF and free from GNB lung infection and colonization followed
at the Copenhagen CF Centre from November 1, 2013 to June 1,
2015, were eligible for the study.
2.2 | Lung infection status
We divided patients into 4 groups according to the bacterial flora6,15:
1. Chronically infected with P. aeruginosa (CF + P (c)) was defined as
presence of this bacterium in 6 consecutive monthly samples or a
shorter period if there were 2 or more precipitating antibodies in
serum.
2. Intermittent lung colonization (CF + P (i)) was defined when P.
aeruginosa, at monthly visits to the clinic, was isolated occasion-
ally but was not present in sputum for 6 months consecutively,
and the anti‐pseudomonas IgG antibodies were not elevated but
within the normal range (0‐1 precipitating antibodies).
3. If the monthly samples had never contained P. aeruginosa previ-
ously, patients were classified as free of P. aeruginosa (CF‐P)
4. Patients colonized/infected in the lungs with other GNB
(Stenotrophomonas maltophilia, Achromobacter xylosoxidans, or
Burkholderia cepacia complex) (CF + GNB). These patients were
not colonized with P. aeruginosa.2.3 | Collection of serum and saliva
Saliva samples were collected from all patients with at least 6 months
interval between sequential samples from each patient. The blood and
saliva samples were obtained simultaneously, as described previously.6
In brief, mixed saliva was collected by using 4 sterile 6‐mm diameter
filterpaper discs (Whatman AA DISCS 6 mm Cat. No. 2017‐006;
Whatman International Ltd, Maidstone, England) which were placed
on the oral mucosa for 30 seconds with a forceps or just dipped in a
container containing mixed saliva from the patient for at least 30 sec-
onds, as described previously.16
2.4 | IgA and IgG against P. aeruginosa
Eluates of saliva from the paper discs were examined for sIgA, and
serum for IgG antibodies, against P. aeruginosa sonicate ((St‐Ag) (O
serogroups 1‐17)), using enzyme‐linked immunosorbent assays
(ELISA), and expressed in optical density values (OD), as reported pre-
viously .6,7,16 The reason for including serum IgG is, that rise of IgG
antibodies is a prognostic sign of a later switch from intermittent to
chronic P. aeruginosa lung infection.4
2.5 | Statistics
We investigated whether antibody measurements could predict if a
patient would change infection status from non‐colonized to
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mixed‐effect logistic regression model. The data span 2 periods, so
some patients are available and contribute to 2 sets of before‐after
status changes which is why we included a random intercept of sub-
ject to account for repeated measurements on some patients. Because
of the small number of events, ie, individuals changing status, we were
only able to include a single predictor at a time.
The number of observations and events were limited in the
dataset, so the logistic regression model could only accommodate a
single predictor before running into problems with complete separa-
tion. Consequently, we first examined if there was any effect of
period, because the 2 periods span different lengths, but no difference
was found. We examined each of the 2 predictors independently using
a logistic regression model with an initial model that included a (log)
linear effect of the predictor as well as the predictor squared to allow
for a nonlinear relationship between the log odds of changing
status and the predictor. However, allowing for nonlinearity did not
contribute anything statistically significant to the model for any of
the predictors, and, therefore, we report the results from the logistic
regression model.
Data were analysed using SAS (SAS Institute Inc., version 9.4, NC,
USA).
2.6 | Ethics
The study was approved by the local ethics committee (H‐1‐2013‐
032). Informed consent was obtained from all patients. Parental
consent was obtained for patients <18 years of age. Obtaining the
saliva samples did not cause any discomfort. This study was carried
out in accordance with the principles of the Helsinki Declaration.FIGURE 1 Change in lung infection status. Forty‐nine CF patients
free from GNB lung colonization were included in this prospective
study. Repeated saliva samples were obtained from each of the
patients with at least a 6‐month interval. However, 21 samples from
our prospective study in 20096 were also included, to increase power.
Consequently, 110 measurements from 49 patients were included. In
the 49 patients, we observed 61 events where patients could change
in lung infection status. The numbers in Table 1 refer to these events.
During a median of 8.5‐months follow‐up, 7 patients changed to
intermittent lung colonization with P. aeruginosa (Pa + (i)), 9 patients
changed to chronic lung infection with P. aeruginosa (Pa + (c)) and 9
patients changes status to lung colonization with other gram‐negative
bacteria (GNB+)3 | RESULTS
Forty‐nine CF patients (28/21 female/male, median age 15 years,
range 5‐45 years) free from lung colonization with P. aeruginosa
(CF‐P) or other GNB, were included in this prospective study. Thirty‐
two patients were dF508 homozygous, 15 were dF508 heterozygous,
and 2 had other mutations.
A total of 110 measurements of s‐IgA in saliva against St‐Ag and
IgG in serum against St‐Ag were analyzed from 49 CF patients. To
increase power, 21 measurements (from 21 patients) obtained in our
prospective study in 20096 were included in these 110 measurements.
We only included measurements on patients who had already agreed
to participate in the present study. During a median of 8.5 months
follow‐up (range 6‐66 months), 25 patients changed their infection
status. Seven patients changed from free of lung colonization to inter-
mittent lung colonization, 9 changed to chronic lung infection, and 9
patients changed to lung colonization or infection with other GNB
(Figure 1).
3.1 | s‐IgA
Mean s‐IgA was higher in patients who changed lung infection status
compared with patients who remained free from lung colonization:
the mean OD was 0.50 and 0.33, respectively (Table 1).Based on the s‐IgA measurements in patients who remained free
of colonization or infection compared with patients with a change in
lung infection status, we constructed a statistical model such that for
a given value of s‐IgA against St‐Ag in saliva, it can predict the proba-
bility of a change (worsening) in lung infection status within the next
8.5 months (median): p = 1 / (1 + exp(−(−0.9582 + 1.6518*IgA)).
The model is plotted in Figure 2 and includes a prediction band
where 95% of new measurements are predicted to fall within. The
model, however, failed to reach statistical significance, as the probabil-
ity was calculated to be P = 0.056, 1‐tailed, using a likelihood‐ratio
test.
3.2 | IgG
Mean serum IgG was higher in patients who changed their lung infec-
tion status compared with patients who remained free from lung
colonization (Table 2). However, the model was inferior compared
with the one with s‐IgA, with regard to detecting a change (P = 0.16,
1‐ tailed), using a likelihood‐ratio test.4 | DISCUSSION
We have previously reported that patients' lung colonized with P.
aeruginosa or other GNB have higher levels of s‐IgA against P.
aeruginosa St‐Ag in saliva than patients free of lung colonization.6 This
may result from a local mucosal antibody response to P. aeruginosa
when it first colonizes the sinuses.
Sinus colonization often precedes intermittent lung colonization
with P. aeruginosa,11 and intermittent colonization precedes chronic
lung infection.2
TABLE 1 Saliva s‐IgA (OD) against P. aeruginosa St‐Ag in CF patients
who remained free of colonization/infection or who became colonized
or infected with P. aeruginosa or other gram‐negative bacteriaa.
LowerQ, upper Q = 25% and 75% quantiles, respectively
Patients' Final
Lung Status
Number of
Observations
Median
sIgA
LowerQ
sIgA
UpperQ
sIgA
Remained free
of colonization/
infection
36 0.24 0.21 0.38
Became colonized/
infected
25 0.38 0.23 0.55
aBurkholderia species, Achromobacter xylosoxidans, Stenotrophomonas
maltophilia.
FIGURE 2 Predicted probability of a change in lung infection status
for a given s‐IgA saliva measurement. This model predicts a probability
for a change in lung infection status for a given IgA OD value, P = 1 /
(1 + exp(−(−0.9582 + 1.6518* within. IgA)). The prediction band
indicates where 95% of new measurements are predicted to fall. The
points in the figure show the predicted probabilities. Y axis is the
probability of a change in lung infection status. X axis refers to the IgA
level in saliva
TABLE 2 Serum IgG (OD) against P. aeruginosa St‐Ag in CF patients
who remained free of colonization/infection or who became colonized
or infected with P. aeruginosa or other gram‐negative bacteriaa.
LowerQ, upper Q = 25% and 75% quantiles, respectively
Patients' Final
Lung Status
Number of
Observations
Median
IgG
LowerQ
IgG
UpperQ
IgG
Remained free of
colonization/
infection
43 1.61 1.06 2.19
Became colonized/
infected
25 2.00 0.23 2.50
aBurkholderia species, Achromobacter xylosoxidans, Stenotrophomonas
maltophilia.
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our saliva s‐IgA model may predict an early worsening in lung infection
status, presumably acting as a surrogate marker of P. aeruginosa or
other GNB mediated bacterial sinusitis and, thereby, identifying
patients at risk of subsequent lung colonization and infection withGNB. However, the model did not reach statistical significance
probably due to limited power, and it must, therefore, be confirmed
in larger prospective studies. Nevertheless, the results from this study
are supported by a recent study by Mauch et al17 who concluded that
s‐IgA measurement can be used as a screening model for patients at
risk of chronic infection.
Measuring IgG levels in serum is a useful tool for identifying
patients at risk of becoming chronically lung infected,4 and we showed
that the s‐IgA model was superior to serum IgG in detecting early
colonization. In this way, the 2 assays may very well supplement each
other consecutively, and we recommend that specific antibodies in
both saliva and serum should be measured regularly.
The reason why s‐IgA is superior at early infections may be a
result of the different action of the immune system in early versus late
infections. When the sinuses are colonized by P. aeruginosa, the
immune response is dominated by a high production of sIgA that binds
to P. aeruginosa antigens and prevent complement activation and the
recruitment of polymorphonuclear leucocytes, thereby, reducing the
inflammatory and systemic response.8,18
Both ESS with adjuvant therapy12,13 and nasal inhalation of antibi-
otics14 can eradicate sinus bacteria, highlighting the importance of
timely intervention against a potential sinonasal bacterial reservoir.
Whether a given s‐IgA value may be helpful to identify patients
who should be offered a sinus eradication attempt even before
intermittent lung colonization occurs, should be investigated in a
clinical trial.
Both ESS13 and administration of topical nasal antibiotics19 are
safe procedures in CF.
Our study has other limitations. The s‐IgA model cannot reliably
distinguish between lung colonization with P. aeruginosa or other
GNB due to cross‐reaction of antibodies against common antigens in
these bacteria, unless absorption studies are carried out.20 However,
ESS has also proven successful in eradicating GNB other than P.
aeruginosa,13 minimizing the importance of exact identification of the
pathogen by serological methods. Nevertheless, there certainly are
different strategies for how aggressively to treat different GNB.
Another limitation of this study is the usage of s‐IgA measure-
ments from our previous published paper.6
Pending on better modalities for detecting upper airway P.
aeruginosa colonization, we believe that s‐IgA saliva measurements
may be a helpful clinical tool. Obtaining saliva samples is very easy
and without any discomfort to the patients including children, and
the IgG assay is commercially available and can easily be modified
for detection of sIgA.11
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